Rhenman & Partners Asset Management AB Acquires 25,500 Shares of Medtronic PLC $MDT

Rhenman & Partners Asset Management AB lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 14.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 205,000 shares of the medical technology company’s stock after purchasing an additional 25,500 shares during the period. Medtronic comprises approximately 2.2% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 13th largest holding. Rhenman & Partners Asset Management AB’s holdings in Medtronic were worth $19,524,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MDT. Norges Bank bought a new stake in Medtronic in the second quarter worth about $1,432,698,000. Barclays PLC grew its position in shares of Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after acquiring an additional 3,492,192 shares during the period. Guinness Asset Management LTD purchased a new stake in shares of Medtronic during the 3rd quarter worth approximately $275,556,000. Vanguard Group Inc. increased its stake in shares of Medtronic by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after purchasing an additional 1,895,165 shares during the last quarter. Finally, Magellan Asset Management Ltd bought a new stake in shares of Medtronic in the 3rd quarter worth approximately $126,347,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $90.83 on Friday. The stock’s 50-day simple moving average is $98.69 and its two-hundred day simple moving average is $96.99. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The firm has a market capitalization of $116.61 billion, a P/E ratio of 25.30, a P/E/G ratio of 2.28 and a beta of 0.71. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the company posted $1.38 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic’s payout ratio is 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved quarterly cash dividend of $0.71 per share (annualized yield ~3.1%), supporting income investors and signaling confidence in cash flow. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Product/market progress in diabetes care with the MiniMed Go Smart MDI system launch in Europe, strengthening Medtronic’s connected diabetes portfolio and long‑term growth potential in CGM/smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Operational tech wins: updates on a Tempus clinical trial and expanded patient‑monitoring alliance with GE HealthCare, which could broaden distribution and adoption of Medtronic devices over time. Digital Alerts and Heart Valves: What Medtronic Investors Should Watch in New Tempus Trial Medtronic, GE HealthCare expand patient monitoring alliance
• Neutral Sentiment: MiniMed priced its IPO at $20 per share and raised about $560M, giving the standalone diabetes unit initial capital and a public valuation backdrop. This is a financing/structuring move that could be positive long term but is mixed near term. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO
• Negative Sentiment: MiniMed’s Nasdaq debut opened below the offering price (shares down ~4.8% on debut), which pressured sentiment toward the spinoff and Medtronic’s value‑unlock story — investors reacted to a softer than expected market reception. Medtronic’s diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
• Negative Sentiment: Medtronic retains ~90% ownership of MiniMed after the IPO, limiting immediate capital release and potential near‑term accretion from the spinoff — this reduces the perceived benefit of the listing for MDT shareholders today. MiniMed (MMED) IPO Falls Flat as Medtronic (MDT) Spinoff Debuts Below Price

Wall Street Analyst Weigh In

Several brokerages have weighed in on MDT. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Morgan Stanley boosted their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Citigroup assumed coverage on Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target for the company. Wells Fargo & Company assumed coverage on Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective for the company. Finally, Daiwa Securities Group lowered their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).